WallStreetZenWallStreetZen

NASDAQ: MLYS
Mineralys Therapeutics Inc Earnings Dates, Reports, Calls

OverviewForecastEarnings
RevenueDividendOwnership
Mineralys Therapeutics earnings were -$151.8M for the trailing 12 months ending Mar 31, 2026, with N/A growth year over year. The latest MLYS earnings report on Mar 31, 2026 announced Q1 2026 earnings of -$39.3M, up 22% from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, MLYS reported annual earnings of -$154.7M, with -13% growth.

MLYS earnings history

Current Revenue
$0.0
Current Earnings
-$151.8M
Current Profit Margin
0%

MLYS Return on Equity

Current Company
-27.9%
Current Industry
-141.9%
Current Market
13.5%
MLYS's Return on Equity (-27.9%)... subscribe to Premium to read more.
High Return on Equity Performance

MLYS Return on Assets

Current Company
-27%
Current Industry
-13.7%
MLYS is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

Be the first to know when MLYS announces earnings.

MLYS Return on Capital Employed

Current Company
-23.78%
Current Industry
-9.5%
MLYS's ability to generate Return... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

MLYS vs Biotech Stocks

TickerEBITDAEarningsY/Y EarningsEPS
MLYS-$151.73M-$151.78MN/A-$2.00
AGIO-$405.69M-$422.60MN/A-$7.25
ZLAB-$150.27M-$178.12MN/A-$1.70
BHVN-$636.53M-$647.68MN/A-$5.58
VCEL$40.42M$21.46M+33.87%$0.43
View Top Biotech Stocks

Mineralys Therapeutics Earnings Reports & History FAQ

What were Mineralys Therapeutics's earnings last quarter?

On MLYS's earnings call on Invalid Date, Mineralys Therapeutics (NASDAQ: MLYS) reported Q1 2026 earnings per share (EPS) of -$0.47, up 40.51% year over year. Total MLYS earnings for the quarter were -$39.34 million. In the same quarter last year, Mineralys Therapeutics's earnings per share (EPS) was -$0.79.

If you're new to stock investing, here's how to buy Mineralys Therapeutics stock.

Is Mineralys Therapeutics profitable or losing money?

As of the last Mineralys Therapeutics earnings report, Mineralys Therapeutics is currently losing money. Mineralys Therapeutics's net profit (also called net income) for the twelve months ending Mar 31, 2026 was -$151.78 million, a 19.49% decrease year over year.

What was MLYS's earnings growth in the past year?

As of Mineralys Therapeutics's earnings date in Invalid Date, Mineralys Therapeutics's earnings has grown year over year. MLYS earnings in the past year totalled -$151.78 million.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.